Pharsight

Drugs that contain Oxymetazoline Hydrochloride

1. Rhofade patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Jan, 2024

(a month ago)

US8420688 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Aug, 2024

(5 months from now)

US7812049 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
May, 2028

(4 years from now)

US8883838 EPI HLTH Pharmaceutical cream compositions and methods of use
Dec, 2031

(7 years from now)

US11517560 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(11 years from now)

Market Authorisation Date: 18 January, 2017

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with ...

Dosage: CREAM;TOPICAL

How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage

RHOFADE family patents

Family Patents

2. Upneeq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357714 RVL PHARMS Compositions and methods for non-surgical treatment of ptosis
Aug, 2031

(7 years from now)

US9867808 RVL PHARMS Compositions and methods for non-surgical treatment of Ptosis
Aug, 2031

(7 years from now)

US10912765 RVL PHARMS Compositions and methods for non-surgical treatment of ptosis
Aug, 2031

(7 years from now)

US11701343 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US10940138 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US10799481 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US10814001 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US10898573 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US11103482 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

US11324722 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

US11541036 RVL PHARMS NA
Dec, 2039

(15 years from now)

US11311515 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jul 8, 2023

Market Authorisation Date: 08 July, 2020

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

UPNEEQ family patents

Family Patents